Precision Optics Corporation, Inc. (POCI) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company increased revenue guidance, expects strong future growth, and achieved breakeven this quarter. Despite a temporary slowdown in aerospace, other programs are expected to offset this. The Q&A reveals positive sentiment from analysts, who are reassured by management's long-term growth plans and profitability expectations. The company's strategic developments, such as the Unity platform and facility expansions, further bolster a positive outlook. Overall, these factors suggest a positive stock price movement over the next two weeks.
Key Financial Performance
Revenue $8.7 million, a new quarterly record, more than double the quarterly revenue of a year ago (108% increase). This growth was driven by strong production demand and improved manufacturing processes and efficiency.
Revenue from Aerospace Program $3.6 million, a new record, representing 44% sequential growth. This was due to investments in production capacity and improved efficiency, with production yields increasing to 97%.
Revenue from Single-Use Cystoscope Program $2.2 million, an all-time high, representing approximately 10% sequential growth. This was attributed to dramatic progress in production yields and cost improvements, with yields increasing to above 90%.
Revenue from Ross Optical Division $1.3 million, compared to $1.0 million in Q2 and $0.8 million a year ago, representing 65% year-over-year growth. Incremental revenue contributed meaningfully to gross profit and adjusted EBITDA.
Gross Margin 24%, compared to 10% a year ago and 3% in Q2. This improvement was due to revenue growth, production improvements, and operational progress.
Adjusted EBITDA Positive $300,000, compared to negative $1.3 million a year ago and negative $1.5 million in the prior sequential quarter. This reflects record revenue, improved manufacturing performance, better yields, and operating expense discipline.
Net Loss $108,000, compared to a net loss of $2.1 million a year ago and $1.8 million in the sequential second quarter. This improvement was driven by operational progress and revenue growth.
Cash $10.7 million as of March 31, 2026, compared to approximately $900,000 at December 31, 2025. This increase was due to an oversubscribed $10 million public offering to support growth plans.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Single-use cystoscope program: Achieved record revenue of $2.2 million in Q3, with production yields improving to above 90% and targeting 95% in Q4.
Single-use ophthalmic endoscope program: Received a $3.5 million follow-on production order, contributing to revenue growth.
Unity platform: Designed to reduce development costs and time to market for reusable and single-use endoscopic systems. Currently has one program in the pipeline and discussions with four additional prospects.
Medical device market: Strong growth trajectory with a focus on minimally-invasive procedures and single-use devices. Disposable income market expected to grow at 15%-20% CAGR over the next 10 years.
Defense/aerospace market: Increased demand for smaller, high-performance optical systems driven by autonomous vehicles and directed energy weapons. Recent participation in SPIE Defense and Security Conference highlights focus.
Satellite communications market: Growing at 15%-25% per year, with opportunities in ground-based and space-based systems.
Revenue growth: Achieved record quarterly revenue of $8.7 million, more than double the previous year, driven by strong production programs.
Gross margin improvement: Improved to 24% in Q3 from 10% a year ago, reflecting better production yields and operational efficiency.
Operational leadership changes: New COO Joe Traut has rebuilt the operations team, leading to significant improvements in production efficiency and yields.
Strategic investments: Focused on enhancing micro-optics production capabilities and expanding market presence in medical devices, defense/aerospace, and satellite communications.
Facility updates: Evaluating updates to manufacturing facilities to support increased production volume.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Scaling Manufacturing Operations: The company is still working through challenges of scaling a much larger manufacturing business, which could impact efficiency and production timelines.
Customer Bottlenecks: A top-tier aerospace customer has faced bottlenecks in their deployment process, leading to a request to slow production in Q1 and Q2 of fiscal 2027, potentially impacting revenue flow.
Production Yields: While production yields have improved, some programs, such as the single-use cystoscope program, have not yet reached targeted efficiency levels, which could affect cost and profitability.
Transitioning Development Programs to Production: There are timeline, yield, and efficiency challenges when transitioning development programs to production, which could delay revenue realization and increase costs.
Investment in Manufacturing Capabilities: The company requires significant investments in quality assurance, manufacturing engineering, supply chain management, and other functions to stabilize and enhance production capabilities, which could strain financial resources.
Economic and Market Risks: The company operates in markets with strong growth trajectories but faces risks from economic uncertainties and market dynamics, particularly in medical devices, defense/aerospace, and satellite communications.
Regulatory and Tariff Challenges: The company has negotiated agreements to pass through tariffs, but regulatory and tariff-related challenges could still impact profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Fiscal 2026 Revenue Guidance: Increased to a range of $29 million to $31 million, up from the previous guidance of $26 million to $28 million. This represents 52% to 62% growth over fiscal 2025 revenue of $19.1 million.
Fiscal 2026 Adjusted EBITDA Guidance: Updated to a range of negative $2.5 million to negative $2.7 million, compared to the previous guidance of negative $2.5 million to negative $3.0 million. This reflects improved operating performance and positive adjusted EBITDA achieved in Q3.
Q4 and Fiscal 2027 Outlook: Anticipates continued strong performance from lead aerospace and cystoscopy production lines, along with the ramping single-use ophthalmic endoscope line. Expects as many as 5 to 6 programs in the development pipeline to move to production in fiscal 2027, with three entering production in the next six months.
New Production Programs: Three programs scheduled to enter production over the next six months include a low-volume single-use device for small joint arthroscopy, an upper GI scope, and a robotic surgery articulating rigid scope.
Ross Optical Revenue: Recent increases in Ross Optical revenues are expected to be sustainable and will continue to contribute to positive margins and bottom-line profitability.
Strategic Investments: Plans to invest in capabilities to become a leading production company in micro-optics, including quality assurance, manufacturing engineering, and supply chain management. Evaluating updates to manufacturing facilities and expanding presence in medical device, defense/aerospace, and satellite communications markets.
Market Growth Projections: Medical device market, particularly disposable income market, expected to grow at a compound annual growth rate of approximately 15% to 20% over the next 10 years. Satellite communications market projected to grow at 15% to 25% per year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you comment on revenue expectations in Q4 for aerospace and the cystoscope? And what do we expect in Q1 for this as well?
A:Revenue for both programs is expected to remain at similar levels as Q3. However, the aerospace program may see a 15%-20% pullback in Q1 and Q2 due to customer-requested slowdown. Other programs coming online are expected to offset this difference, and long-term growth is anticipated.
Q:Can you discuss more about the customer-requested slowdown, and what happens if it moves to a license model?
A:The slowdown is due to the aerospace customer facing challenges in integrating components into satellites, leading to excess inventory. The slowdown is expected to be temporary, with levels returning to normal after a couple of quarters. There is no licensing model for the aerospace program. For the medical device side, licensing involves duplicating production lines in customer facilities, which is seen as a positive development.
Q:With the adoption of Unity, is the time frame for conversion of R&D into production shortened?
A:Yes, the Unity platform shortens the time to production. Currently, only one program is using Unity, but it has shown benefits. The company is working on marketing Unity better and has four potential Unity projects in the sales pipeline, which could increase the product development pipeline.
Q:Do you view the significant increase in sales for Ross Optical this quarter as a new run rate for that business?
A:The increase is believed to be sustainable, driven by new customers, larger orders, and market demand. Some of the increase may also be due to customers replenishing inventory after holding back due to tariff uncertainties.
Q:Can you talk more about growing out the facilities, where the company stands now square footage-wise or other? And where will we be roughly a year from now? What is the capacity utilization currently, and where can we get to on that?
A:The company has made facility updates in Massachusetts and Maine. In Gardner, Massachusetts, there is potential to double the facility size if needed. Current facilities are not ideal, and updates are being considered. Capacity utilization details were not provided, but the company does not expect facility constraints to impede growth.
Q:You mentioned 4 projects in the pipeline. Over what time frame will you get answers on these? And where in magnitude of revenue potential do these projects fit compared to other projects?
A:The four Unity programs in the sales pipeline are expected to generate $1-$3 million annually in production revenue and $1-$2 million during the engineering phase over a couple of years. The timeline for answers on these projects was not specified.
Q:What is the scale of tariff refunds you expect? And will those be passed on to customers?
A:The company is reviewing the scale of tariff refunds. Some refunds will be passed on to customers as per agreements, but not all. The net impact is expected to be positive for the bottom line, though sales will decrease when credit memos are issued.
Q:When will you be able to talk more about specific customers and projects to attract investor and customer interest?
A:The company would like to name specific customers but is restricted by customer policies. They continue to work on this and may confirm details when they become general knowledge in the industry.
Q:As you mentioned in previous calls, pending improvements in the cystoscope line. Have all of these improvements been realized in the third quarter?
A:Not all improvements have been realized. Yield has improved to over 90%, with further improvements expected to reach 95%-98%. Updates to procedures, tools, and fixtures are ongoing to increase throughput and reduce touch time. Continuous improvement is expected over the long term.
Q:Does the industry recognize your momentum? And if so, at what point do you expect revenue to 'hockey stick'?
A:The company senses growing recognition in the industry due to marketing efforts, new facilities, and production capabilities. However, no specific prediction was made for when revenue will 'hockey stick.'
Q:Talk about expectations for profitability.
A:The company achieved breakeven this quarter and expects profitability to grow as new programs and high-margin products come online. The current quarter is seen as an inflection point, with accelerating profitability anticipated moving forward.
Q:Review of Unclear Management Responses
A:The management avoided providing specific timelines for when the four Unity projects in the sales pipeline would yield results. Additionally, they did not provide precise capacity utilization figures or a clear prediction for when revenue would 'hockey stick.'
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Conference
Investments
aerospace satellite
balance sheet
capability
core production
credit
defense aerospace
device defense
director officer
discipline
employee
imaging
improvement
increase production
infrastructure
investor participation
milestone
net tariff
offering
outlook
participation director
production capacity
production volume
profitability
progress
prospect
result visibility
satellite communication
strength core
strength result
use device
use endoscope
visibility remainder
POCI Transcript
Precision Optics Corporation, Inc. (POCI) Q3 2026 Earnings Call Transcript
Positive5-13
The company increased revenue guidance, expects strong future growth, and achieved breakeven this quarter. Despite a temporary slowdown in aerospace, other programs are expected to offset this. The Q&A reveals positive sentiment from analysts, who are reassured by management's long-term growth plans and profitability expectations. The company's strategic developments, such as the Unity platform and facility expansions, further bolster a positive outlook. Overall, these factors suggest a positive stock price movement over the next two weeks.
Precision Optics Corporation, Inc. (POCI) Q2 2026 Earnings Call Transcript
Unknown2-17
Despite some positive developments in the aerospace and cystoscope programs, the company faces significant challenges. Declining gross margins, increased net loss, and negative EBITDA signal financial strain. The Q&A section revealed uncertainties about equity financing and loan success, which could lead to dilution. The strong demand and production improvements may not offset the immediate financial issues, leading to a negative sentiment and potential stock price decline.
Precision Optics Corporation, Inc. (POCI) Q1 2026 Earnings Call Transcript
Positive11-13
The earnings call indicates strong revenue growth, especially in key manufacturing programs, and an optimistic outlook for fiscal 2026 with improved gross margins and positive adjusted EBITDA. The Q&A section did not reveal significant negative trends, and the company's strategic expansion into defense aerospace alongside medical devices suggests diversification and potential profitability. Despite some concerns over gross margins and delayed orders, the overall sentiment is positive, supported by strong revenue expectations and strategic operational investments.
Precision Optics Corporation, Inc. (POCI) Q4 2025 Earnings Call Transcript
Positive9-29
The earnings call reveals record-high quarterly revenue and a significant increase in production revenue, despite a decline in gross margin. The Q&A section confirms conservative but optimistic guidance, with expectations of improved gross margins and a well-prepared pipeline. Management's clear responses and strategic focus on production and engineering projects suggest a positive outlook. The stock price is likely to react positively, with potential gains of 2% to 8% over the next two weeks.
POCI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
